Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Mustang Bio Inc
MBIOCurrent price
1.33 USD
-0.01 USD (-0.75%)
Last closed
1.35 USD
Company
www.mustangbio.com
ISIN
US62818Q1040
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
3 692 386 USD
Yield for 12 month
-92.18 %
1Y
3Y
5Y
10Y
15Y
MBIO
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts. Avenue Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc. Address: 95 Sawyer Road, Waltham, MA, United States, 02453
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
10.00 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
-2 225 000 USD
Current Quarter
–
Last Quarter
–
Key Figures MBIO
1 year
3 years
5 years
10 years
EBITDA
-11 882 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-58.01 %
PEG Ratio
–
Return On Equity TTM
-1 191.31 %
Wall Street Target Price
10.00 USD
Revenue TTM
-50 000 USD
Book Value
-2.12 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-8.65 USD
Diluted Eps TTM
-8.65 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics MBIO
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History MBIO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:50
Payout Ratio
–
Last Split Date
16.01.2025
Stock Valuation MBIO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-0.14
Price Book MRQ
31.75
Financials MBIO
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators MBIO
For 52 weeks
1.15 USD
48.70 USD
50 Day MA
1.85 USD
Shares Short Prior Month
44 005
200 Day MA
9.93 USD
Short Ratio
0.63
Shares Short
60 389
Short Percent
3.17 %
BeatStart